Komori
Pharma Foods International (2929) · TargetAchieved

Stock Acquisition Rights Exercise Conditions Linked to Cumulative Ordinary Profit

First written in FY2016-Q3. 4 of 6 entries say "Advanced", first in FY2021. Latest entry: FY2023.

6entries
8years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2016-Q3AdvancedFY2021 – FY20232016: 120162017: 020172018: 020182019: 020192020: 020202021: 120212022: 320222023: 12023
Same theme, other companies
Cumulative Ordinary Profit Achievement-Linked Stock Acquisition RightsA theme 7 companies write about · 1 as a headwind · 6 as a tailwind

0 other companies' latest entry also says "Achieved".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2023AchievedAnnual report

    「Exercised 5,200 Outstanding and unexercised —」

    All 5,200 remaining shares under the 2016 stock options were exercised, leaving no shares outstanding and unexercised.
  2. FY2022AdvancedAnnual report

    「Exercised 11,700 Outstanding and unexercised 5,200」

    Of the 2016 stock options, 11,700 shares were exercised during the fiscal year under review, leaving 5,200 shares outstanding and unexercised.
  3. FY2022-Q3AdvancedAnnual report

    「1 February 2022–30 April 2022 (Note) 2,300 29,073,800 0 2,042 0 1,892 (Note) Increase due to the exercise of stock acquisition rights.」

    During the third quarter accounting period under review, 2,300 shares were issued through the exercise of stock acquisition rights, bringing the total number of issued shares to 29,073,800.
  4. FY2022-Q2AdvancedAnnual report

    「1 November 2021–31 January 2022 (Note) 8,400 29,071,500 2 2,041 2 1,892 (Note) Increase due to the exercise of stock acquisition rights.」

    During the second quarter accounting period under review, 8,400 shares were issued through the exercise of stock acquisition rights, increasing both stated capital and the capital surplus by ¥2 million.
  5. FY2021AdvancedAnnual report

    「Exercised 18,700 Outstanding and unexercised 16,900」

    Of the 2016 stock options, 18,700 shares were exercised during the fiscal year under review, leaving 16,900 shares outstanding and unexercised.
  6. FY2016-Q3First statedAnnual report

    「A holder of stock acquisition rights may exercise the stock acquisition rights allocated to the holder, up to the percentage specified in each of the following items, if the cumulative amount of ordinary profit in the company's audited statements of income for the fiscal years ending July 2017 and July 2018 (or consolidated statements of income if consolidated financial statements are prepared) meets the following conditions: (a) If it exceeds ¥300 million: 50%; (b) if it exceeds ¥400 million: 80%; (c) if it exceeds ¥500 million: 100%.」

    Exercise conditions were established based on cumulative ordinary profit for the fiscal years ending July 2017 and July 2018, with thresholds of ¥300 million, ¥400 million and ¥500 million.
Moved together

"Research and Development Expenditure" moved the same way as this thread, in the same document, in 5 of its 6 moves.

555544★123456
  1. ★This thread
  2. 1Research and Development Expenditure5×
  3. 2Raising Working Capital through Borrowings5×
  4. 3Expanding Enterprise Value Through the Active Pursuit of M&A5×
  5. 4 적극ive efforts under the Foods with Function Claims system5×
  6. 5Advertising Investment and Product Brand Expansion in Mail-Order Sales4×
  7. 6Development of antibody therapeutics using proprietary chicken antibody technology4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Pharma Foods International yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Stock Acquisition Rights Exercise Conditions Linked to Cumulative Ordinary Profit | Pharma Foods International Co.,Ltd. (2929) | Komori